Using stem cell transplant and Polatuzumab Vedotin for treating B-cell lymphomas

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study investigates the effectiveness of autologous stem cell transplant (ASCT) followed by Polatuzumab Vedotin in patients with various types of B-cell non-Hodgkin lymphoma and Hodgkin lymphoma. Participants will undergo one of two conditioning regimens before receiving ASCT, and if they respond positively, they will receive Polatuzumab Vedotin every 21 days for a total of 8 doses. The study aims to evaluate the treatment's efficacy and safety, with follow-up assessments occurring every four months for approximately two years.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Diagnosis B-cell NHL: Burkitt lymphoma, Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Mantle Cell Lymphoma, Marginal Zone Lymphoma, Transformed Follicular Lymphoma, Richter syndrome, and CD20+ Hodgkin Lymphoma.
* Disease Status Primary Induction Failure, 1st, 2nd or 3rd relapse/progression having attained a CR, PR, or stable disease post reinduction therapy.
* Performance Level Patients must have a performance status ≥ 50%. Use Karnofsky for patients \> 16 years of age and Lansky for patients less than or equal to 16 years of age. See Appendix I for performance score.
* Life Expectancy Patients must have a life expectancy of \> 6 weeks.
* Prior Therapy Patients must have fully recovered from the acute toxic effects of all prior chemotherapy, immunotherapy, or radiotherapy prior to entering this study.

  1. Myelosuppressive chemotherapy: Must not have received within 2 weeks of entry onto this study (4 weeks if prior nitrosourea).
  2. Biologic (anti-neoplastic agent): At least 7 days since the completion of therapy with a biologic agent.
* Organ Function Requirements

Adequate Renal Function Defined As:

* Creatinine clearance or radioisotope GFR \> 60 mL/min/1.73 m2 or
* A serum creatinine based on age/gender as follows:

Age Maximum Serum Creatinine (mg/dL) Male Female

* 12 to \< 13 years 1.2 1.2 13 to \< 16 years 1.5 1.4
* 16 years 1.7 1.4

  * Adequate Liver Function Defined As:

    * Total bilirubin less than or equal to 1.5 x upper limit of normal (ULN) for age, and
    * SGOT (AST) or SGPT (ALT) \< 3 x upper limit of normal (ULN) for age for presumed hepatic leukemia or lymphoma.
  * Adequate Cardiac Function Defined As:

    * Shortening fraction of \> 27% by echocardiogram, or
    * Ejection fraction of \> 50% by radionuclide angiogram.
  * Adequate Pulmonary Function Defined As:

    • Normal respiratory rate for age and a pulse oximetry \> 94% on room air unless due to underlying malignancy.
  * Peripheral Blood Stem Cell Collection

    • Patients have a target of 5.0 x 106 CD34 (minimum of 2.5 x 106 CD34) PBSC collected and cryopreserved prior to start of myeloablative conditioning
  * All patients and/or their parents or legal guardians must sign a written informed consent.

Exclusion Criteria:

* Patient may not have had a prior stem cell transplant
* Patients must not have active CNS lymphoma
* Other concurrent investigational agents for treatment of B-cell lymphoma
* Pregnancy and/or active Breast Feeding
* Sexually active patients of reproductive potential are not eligible unless they have agreed to use an effective contraceptive method for the duration of their study participation.
* Patient must not have an uncontrolled infection.
* Patient must not have ≥ Grade 3 neuropathy.

Where it's running

• New York Medical Center
  Valhalla, New York, United States Recruiting

Study contacts

• Study coordinator: Lauren Harrison, RN
• Email: lauren_harrison@nymc.edu
• Phone: 6172857844

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Treatment for relapsed or refractory B-cell lymphoma using SynKIR-310

  This study is testing a new treatment called SynKIR-310 to see if it can help adults with relapsed or refractory B-cell lymphoma feel better.

  Recruiting at 5 sites Phase 1 Verismo Therapeutics · Denver, Colorado and 4 other locations · NCT06544265

• Gene therapy for certain blood cancers

  This study is testing a new gene therapy called VNX-101 to see if it can help people with certain types of blood cancers that haven't responded to other treatments.

  Recruiting at 11 sites Phase 1/2 Vironexis Biotherapeutics Inc. · Duarte, California and 10 other locations · NCT06533579

• Study of crushed venetoclax tablets dissolved in liquid for pediatric patients

  This study tests if crushing venetoclax tablets and mixing them with liquid helps children with blood cancers absorb the medication better and stay safe while taking it.

  Recruiting at 5 sites Children's Hospital Medical Center, Cincinnati · Aurora, Colorado and 5 other locations · NCT06131801

• Using LV20.19 CAR T-Cells with Pirtobrutinib for B-cell Malignancies

  This study is testing a new treatment combining LV20.19 CAR T-cells with pirtobrutinib to see if it helps adults with tough-to-treat B-cell cancers feel better.

  Recruiting Phase 1 Medical College of Wisconsin · Milwaukee, Wisconsin · NCT05990465

• Local production of CAR T-cells for treating B-Cell cancers

  This study is testing whether making CAR T-cells locally can help patients with B-Cell lymphoma and leukemia have a safe and effective treatment.

  Recruiting Phase 2 Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute) · Pittsburgh, Pennsylvania · NCT05281809

• Rituximab and Tafasitamab with Allogeneic NK Cells for relapsed or refractory B-cell NHL

  This trial tests whether giving allogeneic NK cells with Rituximab, Tafasitamab, and IL-2 can help people with relapsed or refractory B-cell non-Hodgkin lymphoma who have tried at least two prior therapies.

  Recruiting Phase 1 Case Comprehensive Cancer Center · Cleveland, Ohio and 1 other locations · NCT07225439

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.